French maritime pine bark extract is a polyphenol-rich extract standardised for procyanidin content, sold worldwide as a general antioxidant supplement and, in Japan, studied specifically for skin. Brands abroad ask for it as a “brightening” or “anti-photoaging” ingredient.
This guide is for brand owners planning a pine bark extract product made in Japan. It covers what the human trials show, who funded them, how the ingredient is usually formulated, and what to fix before asking for a quotation.
Health supplements are foods, not medicines, and are not a substitute for medical treatment. Nothing here is a claim that any product prevents, treats or cures a disease.
💬 Planning a pine bark extract product made in Japan? We check the full formula against Japanese food law first. See Japan-made supplement OEM.
What the research shows
A 12-week Japanese trial found that oral French maritime pine bark extract reduced skin roughness, wrinkling and pigmentation scores, and a separate placebo-controlled trial in women with melasma found it improved pigmentation scores more than placebo when added to standard treatment.
| Study | Design | Reported result |
|---|---|---|
| Clinical Interventions in Aging 2012;7:275–286 (PMID 22956863) | 112 Japanese women with photoaged facial skin; open-label, dose-comparison trial of 100 mg/day or 40 mg/day pine bark extract against an untreated observation group, 12 weeks (low-dose arm followed further to 18 months) | Significant improvement in skin roughness, wrinkling and melanin-index pigmentation at both doses compared with the untreated group |
| Journal of the European Academy of Dermatology and Venereology 2021;35(2):502–508 (PMID 32841433) | 44 women with facial melasma; randomised, double-blind, placebo-controlled trial of 75 mg pine bark extract twice daily for 60 days, both groups also using sunscreen and a topical triple-combination cream | Modified melasma severity score improved 49% with pine bark extract versus 34% with placebo; global aesthetic improvement 86% versus 55%; no adverse effects reported |
Two caveats to keep in view:
- Design and funding. The 2012 Japanese trial was open-label, not placebo-controlled, and was funded by a research grant from the ingredient’s manufacturer, which also supplied the study tablets. The authors reported no other conflict of interest.
- Population. The 2021 trial was conducted in women with melasma, a diagnosed pigmentation condition, and pine bark extract was tested as an addition to an existing topical treatment, not as a stand-alone product. That is a fact about the research population, not a reason to describe a food product as a melasma treatment.
Checked against the published abstracts on 25 September 2026.
What Japanese products say
Pine bark extract is sold as an ordinary food supplement ingredient in Japan, without the ingredient itself needing a Foods with Function Claims notification to be used.
It appears in tablets and capsules sold through general retail and mail-order channels in Japan, generally marketed around its antioxidant polyphenol content. Where a brand wants a specific function claim under Foods with Function Claims, the notifying business is responsible for the evidence behind the stated function, submitted to the Consumer Affairs Agency before sale.
💬 Need an evidence summary for your regulatory adviser that separates the open-label Japanese trial from the placebo-controlled melasma trial? We prepare it with the manufacturing documents. Tell us your market.
Wording that stays on safe ground
Describe pine bark extract by what was studied and how, not as a treatment for a skin condition.
| Safer wording | Wording to avoid |
|---|---|
| ”Studied for skin roughness and pigmentation appearance" | "Treats melasma” or any disease/condition name attached to the product |
| ”Contains French maritime pine bark extract standardised for procyanidin content" | "Clinically proven” without naming the study, its design and its funding |
| Naming the amount per serving and matching it to a cited study | Copying the melasma trial’s combined-treatment result as if it were the extract alone |
How pine bark extract is formulated
Pine bark extract is dosed in tens to over a hundred milligrams a day and is heat-stable, so it fits small tablets and capsules easily.
| Dosage form | Why brands choose it | What to weigh up |
|---|---|---|
| Tablet | Small daily serving, low cost per day | Standard format for an antioxidant supplement |
| Hard capsule | Simple, flavourless | Suits combined antioxidant or beauty formulas |
Decisions that shape the specification:
- Standardisation. Ask the supplier for the procyanidin content the extract is standardised to, and the plant part and species used.
- Amount per serving. Match the amount to a study you intend to cite — for example 100 mg a day in the 2012 Japanese trial, or 75 mg twice daily in the 2021 melasma trial.
- Companion ingredients. Vitamin C and other antioxidants are common partners in “brightening” formulas. Each needs its own check against Japanese food law.
- Market status. Pine bark extract’s status as a food supplement ingredient differs between countries. Confirm it before you commit to a formula.
The check that comes first
Every ingredient must be permitted in foods in Japan, or a Japanese factory cannot make the product.
Pine bark extract itself is widely sold as a food in Japan. Beauty formulas that combine it with botanical extracts sometimes run into ingredients Japan treats as medicines, and that is usually where the risk sits. See the Japan-made supplement OEM page, and our hyaluronic acid and vitamin C guides if you plan a combined brightening product.
Before you ask for a quotation
A factory can quote accurately once the standardisation, the amount, the form and the companions are fixed.
- Procyanidin standardisation and plant source
- Amount per serving and servings per pack
- Dosage form
- Companion ingredients and their amounts
- Countries you will sell in, and pine bark extract’s status there
- First order and annual volume
💬 Ready to design a Japan-made pine bark extract product? Send us the concept — amount, form, companion ingredients and the countries you will sell in.
Frequently asked questions
1. Does oral pine bark extract help photoaged or pigmented skin?
A 2012 Japanese trial in 112 women found improved skin roughness, wrinkling and pigmentation scores at 100 mg or 40 mg a day over 12 weeks, though the design was open-label and industry-funded rather than placebo-controlled. A 2021 placebo-controlled trial in women with melasma found a bigger improvement with pine bark extract added to standard treatment than with the treatment alone.
2. Was the Japanese trial placebo-controlled?
No. It compared two doses of pine bark extract against an untreated observation group, without a placebo, and was funded by a grant from the ingredient’s manufacturer, which also supplied the tablets.
3. Can pine bark extract be described as a melasma treatment?
No. The melasma trial tested pine bark extract as an addition to an existing topical treatment and sunscreen in a diagnosed patient population, and a food supplement cannot carry treatment claims for a named skin condition regardless of what a trial in patients found.
4. What is pine bark extract standardised for?
Procyanidin content, a class of polyphenols built from catechin and epicatechin units. Ask your supplier for the exact standardisation and the plant source.
5. What can stop a Japanese factory making my pine bark extract product?
Usually a companion botanical in a combined “brightening” or “anti-ageing” formula. Every ingredient must be permitted in foods in Japan, so we check the full formula first.
Sources: “Oral administration of French maritime pine bark extract improves clinical symptoms in photoaged facial skin”, Clinical Interventions in Aging 2012;7:275–286 (PMID 22956863); “French maritime pine bark extract (pycnogenol) in association with triple combination cream for the treatment of facial melasma in women: a double-blind, randomized, placebo-controlled trial”, Journal of the European Academy of Dermatology and Venereology 2021;35(2):502–508 (PMID 32841433); Consumer Affairs Agency notifications for Foods with Function Claims. Checked on 25 September 2026.